CJC-1295 with DAC 51753-57-2

Basic Info.

Model NO.:51753-57-2 Function:Hormones and Regulation of Endocrine Function of Drug, Vitamins and Minerals Deficiency Drug, Nutritional Therapeutics Certification:GMP, Reach, SGS, FDA Grade Standard:Medicine Grade Type:Analysis reagent State:Solid Volatile:Not Volatile Product Name:Cjc1295 Dac CAS:51753-57-2 Appearance:White Powder Purity (HPLC):98% Unit Size:2mg/Vial Usage:Muscle Building Export Markets:Global Additional Info.

Trademark:Saichuang Packing:Vial or as Require Standard:ISO9001 Origin:China HS Code:3001200020 Production Capacity:5000vial Product Description CJC1295 DAC Product Name:CJC1295 DAC;CJC1295 with DAC Alias: CJC1295(GHRH/DAC) Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-LysLys(Maleimidopropionyl)-NH2 (Drug Affinity Complex) Density:1.45 CJC-1295 with DAC Product Description: CJC-1295 2mg/Vial Type: Immune Function AgentsGrade Standard: Medicine Grade Classification: Brassinosteroid CAS: 51753-57-2 MF: C165H271N47O46 Molecular Weight: 3649.30 Purity (HPLC): 98.0% Appearance: White powder Single Impurity(HPLC): 1.0% Amino Acid Composition: 10% of theoretical Peptide Content(N%): 80%(by %N) Water Content(Karl Fischer): 6.0% Acetate Content(HPIC): 15.0% Mass Balance: 95.0~105.0% Function: Hormones and Regulation of Endocrine Function of D

Usage: CJC-1295 DAC has shown some amazing results as a hormone releasing hormone (GHRH) analog. Not only has CJC-1295 shown the ability to increase hormone and secretion and its benefits, but it has been able to do so in very large amounts.

Recent research studies have shown that CJC - 1295 stimulates GH and Secretion, and will keep a steady increase with no increase in prolactin, leading to intense fat loss, and increases protein synthesis. CJC-1295 DAC is a long acting Hormone Releasing Hormone, which causes the anterior pituitary to release more hormone.

GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (-hormone inhibiting-hormone). Clinical Research was first conducted for CJC-1295 during the MID-2000s.

The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects.

Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies shows that combining a GHRP-6 with CJC 1295 DAC, significantly increase the release of GH and production without an increase in prolactin.

An example of a GHRP (GH Releasing Peptide) is Hexarelin or GHRP-2. CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin and protects the CJC-1295 DAC peptide from degradation.

This was formed when a lysine link was bounded to DACS to a reactive chemical called maleimidoproprionic acid (MPa).